Condition

Metastatic Pancreatic Adenocarcinoma (2)

Recurrent Pancreatic Adenocarcinoma (2)

Stage II Pancreatic Cancer AJCC v8 (1)

Stage III Pancreatic Cancer AJCC v8 (1)

Stage IV Pancreatic Cancer AJCC v6 and v7 (1)

Stage IV Pancreatic Cancer AJCC v8 (1)

Unresectable Pancreatic Carcinoma (1)

Overall Status

Active, not recruiting (2)

Phase

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

M.D. Anderson Cancer Center (1)

National Cancer Institute (NCI) (1)

Collaborator

National Cancer Institute (NCI) (1)

Intervention

anetumab ravtansine (1)

biopsy (1)

biospecimen collection (1)

cxcr4 antagonist bl-8040 (1)

gemcitabine hydrochloride (1)

ipilimumab (1)

nivolumab (1)

pembrolizumab (1)

pharmacological study (1)

Study Documents

Intervention Type

biological (2)

drug (2)

other (1)

procedure (1)

Funder Type

NIH (1)

Other (1)

Study Type

Interventional (2)

recurrent pancreatic adenocarcinoma

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 Trial in Canada,

Active, not recruiting

Metastatic Pancreatic Adenocarcinoma
+5 more

Anetumab Ravtansine
+5 more

Birmingham, Alabama
+44 more

Feb 2, 2023

Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7 Trial in

Active, not recruiting

Metastatic Pancreatic Adenocarcinoma
+2 more

CXCR4 Antagonist BL-8040
+2 more

Houston, Texas

M D Anderson Cancer Center

Feb 9, 2022